Journal
CANCER LETTERS
Volume 390, Issue -, Pages 188-200Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.12.037
Keywords
Chimeric antigen receptor; Modified T cells; Solid tumor; Clinical trials; Immunotherapy
Categories
Funding
- National Health and Medical Research Council of Australia (NHMRC) [1047417]
- Cancer Council NSW grant [APP1070076]
- Cancer Council New South Wales [APP1069733]
- James Cook University Development Grant [94066]
- Cancer Council Queensland [APP1123436]
Ask authors/readers for more resources
Chimeric antigen receptors (CARs) are a series of manufactured receptors that have the capacity of binding to specific antigens expressed on surface of tumor cells. A CAR normally has an extracellular antigen recognition domain derived from single variable chain of a monoclonal antibody, a trans membrane domain and an intracellular T cell activation domain. During the last decade, CAR-T cells were demonstrated to possess great therapeutic effects on hematological malignancies. However, strategies using CAR-T cells to treat solid tumors have been hindered by considerable obstacles including on tissue off target effects and cytokine storm syndrome. This review will summarize the current understanding of CAR-T cell therapies and briefly describe the currently enrolled clinical trials in solid tumors. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available